PABPC1P13

Across TCGA pan-cancer cohorts, PABPC1P13 RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated PABPC1P13 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PABPC1P13 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PABPC1P13 expression acts as an unfavorable survival marker.

LUAD, DLBC, and CESC are the cancer types where PABPC1P13 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.355	0.796	<.001	90	view →
DLBC	OS	Tertile	II,III,IV	0.172	0.949	<.001	84	view →
CESC	DFS	Tertile	III,IV	0.240	0.726	.015	18	view →
LUSC	OS	Tertile	III,IV	0.011	0.664	<.001	18	view →
ACC	DFS	Tertile	II,III,IV	0.226	0.725	.009	18	view →
STAD	DFS	Tertile	All	0.561	0.676	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PABPC1P13–LUAD (OS)

Open the LUAD breakdown →